Coherus Oncology reported interim clinical data for tagmokitug, its investigational cytolytic CCR8 antibody, in combination with toripalimab, with or without chemotherapy, across solid tumors including esophageal squamous cell carcinoma (ESCC). In evaluable front-line ESCC, the company reported a confirmed overall response rate of 75% regardless of PD-L1 status, rising to 100% in PD-L1-positive patients as of Oct. 14, 2026. The update supports further ESCC cohort expansion, with the company citing a manageable safety profile and additional post-cutoff confirmed responses. For immuno-oncology competitors, CCR8-directed cytolytic approaches could influence how clinicians sequence immunotherapy lines if responses are sustained and tolerability holds.